专业监测看板

Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

药物 / 成分：Nivolumab、Gemcitabine、Cisplatin、Nivolumab/Relatlimab

登记的停止原因（原文）：The study was terminated due to administrative reasons following the cancellation of collaboration between the involved parties.

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

药物 / 成分：[18F]-FDG

登记的停止原因（原文）：Unable to recruit for this study.

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

药物 / 成分：EffCaMgCit、Placebo

登记的停止原因（原文）：No enrollment due to COVID

Transition From Acute to Chronic Opioid Use and Chronic Pain

药物 / 成分：Opioid-free anesthesia、Opioid-based anesthesia

登记的停止原因（原文）：Study did not receive funding.

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

药物 / 成分：Sulforaphane

登记的停止原因（原文）：Had issue enrolling subjects.

A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF

药物 / 成分：Anakinra

登记的停止原因（原文）：Business decision.

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

药物 / 成分：CABA-201

登记的停止原因（原文）：The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio.

A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma

药物 / 成分：tolododekin alfa

登记的停止原因（原文）：Strategic realignment

Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia

药物 / 成分：90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG、Busulfan、allogeneic stem cell transplantation.、Fludarabine

Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients

药物 / 成分：1.25mg bevacizumab、2.50mg bevacizumab

登记的停止原因（原文）：Unable to enroll patients for the trial.

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

药物 / 成分：LCAR-AIO T cells

登记的停止原因（原文）：Legend discontinues the development of the IMP.

A Clinical Study of Ultrasound-guided Botulinum Toxin A Into Salivary Gland for Sialorrhea After True Bulbar Palsy

药物 / 成分：Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection、Control (Normal saline)

登记的停止原因（原文）：In accordance with the time-limit regulations for ethical review, since the ethical approval certificate of this study protocol has expired, I hereby formally apply for the withdrawal of this study from the clinical trial registration platform.

A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

药物 / 成分：gene therapy、gene therapy

登记的停止原因（原文）：Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

药物 / 成分：Decitabine、Nivolumab

登记的停止原因（原文）：PI leaving the institution

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

药物 / 成分：Drug: Nogapendekin alfa inbakicept (NAI)、Pembrolizumab、Cisplatin or Carboplatin、Nab-paclitaxel (squamous) OR Pemetrexed (nonsquamous)

登记的停止原因（原文）：Sponsor decision

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

药物 / 成分：ERW316、Fulvestrant、Letrozole

登记的停止原因（原文）：Business decision

System for Measuring Non-invasive Blood Flow in the Tracheobronchial Mucosa: Validation of Reproducibility

药物 / 成分：Blood flow to the tracheo-bronchial mucosa

登记的停止原因（原文）：20131209 Regulatory authorization is currently blocked at the ANSM.

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

药物 / 成分：Empagliflozin

登记的停止原因（原文）：The study was not initiated because the planned prospective design was no longer feasible in routine clinical practice before participant enrollment.

A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

药物 / 成分：Linvoseltamab、Bortezomib、Lenalidomide、Daratumumab

登记的停止原因（原文）：Sponsor Decision

Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine

药物 / 成分：Reference、Experimental

登记的停止原因（原文）：No inclusions.